I 
116TH CONGRESS 
2D SESSION 
H. R. 7104 
To direct the Secretary of Health and Human Services to award contracts, 
grants, and cooperative agreements to expand and enhance manufac-
turing capacity of vaccines and vaccine candidates to prevent the spread 
of SARS–CoV–2 and COVID–19. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 4, 2020 
Ms. KUSTER of New Hampshire (for herself and Mr. JEFFRIES) introduced 
the following bill; which was referred to the Committee on Energy and 
Commerce 
A BILL 
To direct the Secretary of Health and Human Services to 
award contracts, grants, and cooperative agreements to 
expand and enhance manufacturing capacity of vaccines 
and vaccine candidates to prevent the spread of SARS– 
CoV–2 and COVID–19. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. VACCINE MANUFACTURING AND ADMINISTRA-
TION CAPACITY. 
(a) ENHANCING MANUFACTURING CAPACITY.— 
(1) IN GENERAL.—The Secretary of Health and 
Human Services (in this section referred to as the 
VerDate Sep 11 2014 
02:29 Jun 27, 2020
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H7104.IH
H7104
ctelli on DSK30NT082PROD with BILLS
‘‘Secretary’’) acting through the Director of the Bio-
medical Advanced Research and Development Au-
thority shall, as appropriate, award contracts, 
grants, and cooperative agreements, and enter into 
other transactions, to expand and enhance manufac-
turing capacity of vaccines and vaccine candidates to 
prevent the spread of SARS–CoV–2 and COVID–19. 
(2) AUTHORIZATION OF APPROPRIATIONS.—To 
carry out this subsection, there are authorized to be 
appropriated such sums as may be necessary for fis-
cal years 2020 through 2024, to remain available 
until expended. 
(b) REPORT ON VACCINE MANUFACTURING AND AD-
MINISTRATION CAPACITY.— 
(1) IN GENERAL.—Not later than December 31, 
2020, the Secretary shall submit to the Committee 
on Energy and Commerce of the House of Rep-
resentatives and the Committee on Health, Edu-
cation, Labor and Pensions of the Senate a report 
detailing— 
(A) an assessment of the estimated supply 
of vaccines and ancillary medical products re-
lated to vaccine administration necessary to 
control and stop the spread of SARS–CoV–2 
VerDate Sep 11 2014 
04:14 Jun 24, 2020
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H7104.IH
H7104
ctelli on DSK30NT082PROD with BILLS
and COVID–19, domestically and internation-
ally; 
(B) an assessment of current and future 
domestic manufacturing capacity for vaccines or 
vaccine candidates to control or stop the spread 
of SARS–CoV–2 and COVID–19, vaccine can-
didates, and ancillary products related to the 
administration of such vaccines, including iden-
tification of any gaps in manufacturing capac-
ity; 
(C) activities conducted to expand and en-
hance manufacturing capacity for vaccines, vac-
cine candidates, and ancillary medical products 
to levels sufficient to control and stop the 
spread of SARS–CoV–2 and COVID–19, do-
mestically and internationally, including a list 
and explanation of all contracts, grants, and co-
operative agreements awarded, and other trans-
actions entered into, for purposes of such ex-
pansion and enhancement and how such activi-
ties will help to meet future domestic manufac-
turing capacity needs; 
(D) a plan for the ongoing support of en-
hanced manufacturing capacity for vaccines, 
vaccine candidates, and ancillary medical prod-
VerDate Sep 11 2014 
04:14 Jun 24, 2020
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H7104.IH
H7104
ctelli on DSK30NT082PROD with BILLS
ucts sufficient to control and stop the spread of 
SARS–CoV–2 and COVID–19, domestically 
and internationally; and 
(E) a plan to support the administration of 
vaccines approved or authorized by the Food 
and Drug Administration to control and stop 
the spread of SARS–CoV–2 and COVID–19, 
domestically and internationally, including Fed-
eral workforce enhancements necessary to ad-
minister such vaccines. 
(2) ANCILLARY MEDICAL PRODUCTS.—For pur-
poses of this subsection, ‘‘ancillary medical prod-
ucts’’ includes— 
(A) vials; 
(B) bandages; 
(C) alcohol swabs; 
(D) syringes; 
(E) needles; 
(F) gloves and other personal protective 
equipment; and 
(G) other medical products the Secretary 
determines necessary for the administration of 
vaccines. 
Æ 
VerDate Sep 11 2014 
04:14 Jun 24, 2020
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H7104.IH
H7104
ctelli on DSK30NT082PROD with BILLS